...
首页> 外文期刊>Molecular genetics and metabolism >Recurrence of carbamoyl phosphate synthetase 1 (CPS1) deficiency in Turkish patients: Characterization of a founder mutation by use of recombinant CPS1 from insect cells expression
【24h】

Recurrence of carbamoyl phosphate synthetase 1 (CPS1) deficiency in Turkish patients: Characterization of a founder mutation by use of recombinant CPS1 from insect cells expression

机译:土耳其患者中氨基甲酰磷酸合成酶1(CPS1)缺乏症的复发:通过使用昆虫细胞表达中的重组CPS1来鉴定创始人突变

获取原文
获取原文并翻译 | 示例
           

摘要

Carbamoyl phosphate synthetase 1 (CPS1) deficiency due to CPS1 mutations is a rare autosomal-recessive urea cycle disorder causing hyperammonemia that can lead to death or severe neurological impairment. CPS1 catalyzes carbamoyl phosphate formation from ammonia, bicarbonate and two molecules of ATP, and requires the allosteric activator N-acetyl-L-glutamate. Clinical mutations occur in the entire CPS1 coding region, but mainly in single families, with little recurrence. We characterized here the only currently known recurrent CPS1 mutation, p.Val1013del, found in eleven unrelated patients of Turkish descent using recombinant His-tagged wild type or mutant CPS1 expressed in baculovirus/insect cell system. The global CPS1 reaction and the ATPase and ATP synthesis partial reactions that reflect, respectively, the bicarbonate and the carbamate phosphorylation steps, were assayed. We found that CPS1 wild type and V1013del mutant showed comparable expression levels and purity but the mutant CPS1 exhibited no significant residual activities. In the CPS1 structural model, V1013 belongs to a highly hydrophobic beta-strand at the middle of the central beta-sheet of the A subdomain of the carbamate phosphorylation domain and is close to the predicted carbamate tunnel that links both phosphorylation sites. Haplotype studies suggested that p.Val1013del is a founder mutation. In conclusion, the mutation p.V1013del inactivates CPS1 but does not render the enzyme grossly unstable or insoluble. Recurrence of this particular mutation in Turkish patients is likely due to a founder effect, which is consistent with the frequent consanguinity observed in the affected population. (C) 2014 Elsevier Inc All rights reserved.
机译:由于CPS1突变引起的氨基甲酸酯磷酸合成酶1(CPS1)缺乏是罕见的常染色体隐性尿​​素循环障碍,引起高氨血症,可导致死亡或严重的神经功能障碍。 CPS1催化氨,碳酸氢根和两个ATP分子形成氨基甲酸酯磷酸,并需要变构活化剂N-乙酰基-L-谷氨酸。临床突变发生在整个CPS1编码区域,但主要在单个家族中发生,很少复发。我们使用在杆状病毒/昆虫细胞系统中表达的重组组氨酸标签的野生型或突变体CPS1,在11名不相关的土耳其血统患者中发现了目前唯一已知的CPS1复发突变p.Val1013del。分析了总体CPS1反应以及分别反映碳酸氢盐和氨基甲酸酯磷酸化步骤的ATPase和ATP合成部分反应。我们发现CPS1野生型和V1013del突变体表现出可比的表达水平和纯度,但突变体CPS1没有表现出明显的残留活性。在CPS1结构模型中,V1013属于氨基甲酸酯磷酸化结构域A子结构域的中央β-折叠中心的高度疏水性β-链,并且靠近连接两个磷酸化位点的预测氨基甲酸酯通道。单倍型研究表明p.Val1013del是创始人突变。总之,突变p.V1013del使CPS1失活,但不会使酶严重不稳定或不溶。土耳其患者中这种特定突变的复发很可能是由于建立者效应,这与在受影响人群中观察到的频繁血缘相一致。 (C)2014 Elsevier Inc保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号